ASCO 2020

COVID-19 & Telemedicine

COVID-19 and Cancer Consortium Registry: initial results

Presented By

Prof. Jeremy L. Warner, Vanderbilt-Ingram Cancer Center, USA

Trial

COVID-19 and Cancer Consortium Registry (CCC19)

Conference

ASCO 2020

28 August, 2020 15:00

Oncology hospital-at-home model reduces hospitalizations, emergency department visits, and costs

Expert

Prof. Kathi Mooney, University of Utah Huntsman Cancer Institute

Conference

ASCO 2020

28 August, 2020 14:23

Nurse-led telephone triage system reduces hospitalizations, helps patients manage symptoms at home 

Expert

Dr. Lorenzo Calvetti, San Bortolo Hospital in Vincenza, Italy

Conference

ASCO 2020

28 August, 2020 14:20

Melanoma

Adjuvant pembrolizumab: durable RFS for stage III melanoma

Presented By

Prof. Alexander Eggermont, Princess Máxima Centre, NL

Trial

Phase 3, EORTC 1325-MG/KEYNOTE-054

Conference

ASCO 2020

28 August, 2020 15:45

Pembrolizumab plus low-dose ipilimumab well tolerated after progression on PD1 antibody therapy

Principal Investigator

Dr Daniel Olson, The University of Chicago Comprehensive Cancer Center, IL, USA

Trial

Phase 2

Conference

ASCO 2020

28 August, 2020 15:05

Toripalimab plus axitinib effective in metastatic mucosal melanoma

Presented By

Dr Xinan Sheng, Peking University Cancer Hospital and Institute, China

Trial

Phase 1

Conference

ASCO 2020

28 August, 2020 14:13

Melanoma incidence continues to rise in Europe

Conference

AAD 2018

20 December, 2018 18:15

Lesions in paediatric patients and possible correlation with coffee drinking

Presented By

Dr Ryan Kelm, Feinberg School of Medicine

Conference

AAD 2018

20 December, 2018 17:22

CNNs and targeted combination therapy

Presented By

Dr Allan Halpern, Memorial Sloan Kettering Cancer Center

Conference

AAD 2018

20 December, 2018 15:27

Breast & Ovarian Cancer

Advanced breast cancer: locoregional therapy does not improve OS

Presented By

Prof. Seema A. Khan, Feinberg School of Medicine, USA

Trial

Phase 3, E2108

Conference

ASCO 2020

8 September, 2020 09:50

T-DM1 does not improve safety or efficacy in HER-2 positive early breast cancer; favorable iDFS reported

Presented By

Prof. N. Harbeck, University of Munich, Germany

Trial

Phase 3, KAITLIN

Conference

ASCO 2020

8 September, 2020 09:40

Maintenance olaparib improves OS in relapsed ovarian cancer with BRCA1/2 mutation

Presented By

Prof. Andrés Poveda, Hospital Quironsalud, Spain

Trial

Phase 3, SOLO2/ENGOT-ov21

Conference

ASCO 2020

8 September, 2020 09:35

Combination pembrolizumab/chemo improves PFS in metastatic TNBC

Presented By

Dr Javier Cortés, Vall d’Hebron Institute of Oncology, Spain & Catherine M. Kelly, Mater Misericordiae University Hospital, Ireland

Conference

ASCO 2020

8 September, 2020 09:32

Effect of veliparib with or without cisplatin in breast cancer: results of SWOG S1416

Presented By

Dr Priyanka Sharma, University of Kansas Medical Center, USA

Trial

Phase 2, SWOG 1416

Conference

ASCO 2020

8 September, 2020 09:30

PHOEBE, a phase 3 trial comparing pyrotinib and lapatinib in HER2-positive metastatic breast cancer

Presented By

Dr Binghe Xu, Peking Union Medical College, China

Trial

Phase 3, PHOEBE

Conference

ASCO 2020

8 September, 2020 09:10

BYLieve demonstrates efficacy of PIK3CA-directed treatment post CDK4/6-ihibition

Presented By

Prof. Hope S. Rugo, University of California San Francisco, CA, USA

Trial

Phase 2, BYLieve

Conference

ASCO 2020

8 September, 2020 09:00

Strategies emerge for chemotherapy de-escalation in HER2-positive breast cancer

Presented By

Dr Javier Cortés, Vall d’Hebron Institute of Oncology, Spain

Trial

Phase 2, PHERGAIN

Conference

ASCO 2020

8 September, 2020 08:50

Multiple Myeloma

Carfilzomib: no PFS benefit for multiple myeloma

Presented By

Prof. Shaji K. Kumar, Mayo Clinica, MN, USA

Trial

Phase 3, ENDURANCE (E1A11)

Conference

ASCO 2020

28 August, 2020 16:00

Isatuximab triplet improves PFS in R/R MM

26 August, 2020 11:26

Isatuximab triplet improves PFS in R/R MM

16 June, 2020 07:51

CASSIOPEIA trial: Phase 3 results of daratumumab + bortezomib/thalidomide/dexamethasone in multiple myeloma

Expert

Prof. Phillippe Moreau, University Hospital of Nantes, France

Trial

Phase 3, CASSIOPEIA

Conference

EHA 2019

9 August, 2019 23:30

Lung Cancer

ES-SCLC: tremelimumab + durvalumab + chemotherapy misses endpoint

Presented By

Prof. Luis G. Paz-Ares, Hospital 12 de Octubre, Spain

Trial

Phase 3, CASPIAN

Conference

ASCO 2020

8 September, 2020 13:50

Adjuvant osimertinib in NSCLC: practice changing ADAURA trial

Presented By

Prof. Roy S. Herbst, Yale Cancer Center, USA

Trial

Phase 3, ADAURA

Conference

ASCO 2020

8 September, 2020 13:39

ES-SCLC: pembrolizumab KEYNOTE-604 data

Presented By

Dr Charles M. Rudin, Memorial Sloan Kettering Cancer Center, USA

Trial

Phase 3, KEYNOTE-604

Conference

ASCO 2020

8 September, 2020 13:20

Second-line gemcitabine plus ramucirumab significantly improves overall survival

Presented By

Dr Maria Pagano, General Hospital Arcispedale Santa Maria Nuova, Italy

Trial

Phase 2, RAMES

Conference

ASCO20

8 September, 2020 13:17

Tiragolumab and atezolizumab: ORR in NSCLC

Presented By

Dr Delvys Rodriguez-Abreu, NYU Perlmutter Cancer Center, USA

Trial

Phase 2, CITYSCAPE

Conference

ASCO 2020

8 September, 2020 13:15

MET-amplified advanced NSCLC responds well to MET inhibitor capmatinib

Presented By

Prof. Jürgen Wolf, University Hospital Cologne, Germany

Trial

Phase 2, GEOMETRY

Conference

ASCO 2020

8 September, 2020 13:07

Genitourinary Cancer

Urothelial cancer: avelumab works as maintenance therapy

Expert

Prof. Thomas Powles, Barts Cancer Institute, UK

Trial

Phase 3, JAVELIN Bladder 100

Conference

ASCO 2020

17 September, 2020 14:30

ARAMIS final OS and nmCRPC safety outcomes

Expert

Prof. Karim Fizazi, Institut Gustave Roussy, France

Trial

Phase 3, ARAMIS

Conference

ASCO 2020

17 September, 2020 14:11

Final survival results from phase 3 SPARTAN trial

Expert

Prof. Eric J. Small, University of California San Francisco, CA, USA

Trial

Phase 3, SPARTAN

Conference

ASCO 2020

17 September, 2020 14:01

Novel drug for kidney cancers/VHL patients

Expert

Prof. Eric Jonasch, University of Texas MD Anderson Cancer Center, USA

Trial

Phase 2

Conference

ASCO 2020

17 September, 2020 13:59

Primary analysis from IMvigor010, adjuvant atezolizumab in high risk muscle-invasive urothelial carcinoma

Expert

Dr Maya H.A. Hussain, Northwestern University in Chicago, IL, USA

Trial

Phase 3, IMvigor010

Conference

ASCO 2020

17 September, 2020 13:57

First randomised trial of Lu-PSMA in mCRPC progressing after docetaxel

Expert

Prof. Michael S. Hofman, Peter MacCallum Cancer Centre, Australia

Trial

TheraP

Conference

ASCO 2020

17 September, 2020 13:54

Gastrointestinal Cancer

HER2-expressing metastatic colorectal cancer: trastuzumab deruxtecan

Expert

Prof. Salvatore Siena, University of Milan Niguarda Cancer Center, Italy

Trial

Phase 3, DESTINY-CRC01

Conference

ASCO 2020

17 September, 2020 15:00

Pembrolizumab as first-line in MSI-H mCRC

Expert

Prof. Thierry André, St Antoine Hospital, France

Trial

Phase 3, KEYNOTE-177

Conference

ASCO 2020

17 September, 2020 14:55

REGOMUNE: a phase 2 study combining regorafenib and avelumab

Expert

Dr Sophie Cousin, Institut Bergonié, France

Trial

Phase 1/2, REGOMUNE

Conference

ASCO 2020

17 September, 2020 14:52

Cardiotoxicity: consider switching to S-1

Expert

Prof. Pia Österlund, Tampere University Hospital, Finland

Conference

ASCO 2020

17 September, 2020 14:49

Perioperative chemotherapy for resectable pancreatic ductal adenocarcinoma

Expert

Prof. Davendra Sohal, University of Cincinnati, OH, USA

Trial

Phase 2, SWOG S1505

Conference

ASCO 2020

17 September, 2020 14:47

Real-world data of sequential sorafenib followed by regorafenib in unresectable HCC

Expert

Dr Philippe Merle, Groupement Hospitalier Lyon Nord, France

Trial

REFINE

Conference

ASCO 2020

17 September, 2020 14:45

Paediatric Cancer

Sustained improvements in quality of life with larotrectinib

Expert

Prof. Shivaani Kummar, Stanford School of Medicine, CA, USA

Trial

Phase 2 NAVIGATE, phase 1/2 SCOUT

Conference

ASCO 2020

9 September, 2020 14:20

Promising first immunotherapy trial in placental trophoblastic tumours

Expert

Prof. Benoit You, Lyon University Hospital, France

Trial

Phase 2, TROPHIMMUN

Conference

ASCO 2020

9 September, 2020 14:17

Precision medicine for poor-prognosis paediatric patients

Expert

Prof. Cornelis van Tilburg, Hopp Children’s Cancer Center, Germany

Trial

INFORM

Conference

ASCO 2020

9 September, 2020 14:00